Psoriatic Arthritis Quality of Life Questionnaire: translation, cultural adaptation and validation into Brazilian Portuguese language

Gonçalves, Rafaela Silva Guimarães; Heaney, Alice; McKenna, Stephen P.; Carvalho, Jonas Braynner; Vidal, Maria Eduarda Lima; Brito, Marina Coelho Mores de; Duarte, Ângela Luzia Branco Pinto

doi:10.1186/s42358-021-00168-6

Cited by 4 publications

(4 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was comparable to the Greek result (Heaney et al, 2017) and higher than all other adaptation studies (Barcelos et al, 2018;Billing et al, 2010;Gonçalves et al, 2021;Kiltz et al, 2021;Leung et al, 2016;Wink et al, 2013).…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language

Tekaya

Hajji

Rouached

et al. 2023

Musculoskeletal Care

View full text Add to dashboard Cite

BackgroundPsoriatic arthritis (PsA) is a multifaceted inflammatory disease that has a strong negative impact on the quality of life (QoL) of patients. The Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire was the first disease‐specific patient‐derived instrument developed to measure the QoL in patients with PsA. Our objective was to translate the PsAQol into Arabic language and evaluate its reliability and validity in patients with PsA.MethodsThis was a cross‐sectional study including patients with PsA. A clinical and biological assessment of the patients was performed at inclusion. The translation of the original PsAQoL into Arabic was performed by a professional bilingual and lay panel. Eight patients were interviewed to assess face and content validity. A separate sample of PsA patients (n = 30) were invited to participate in a test‐retest postal study in order to investigate reproducibility and construct validity. One week separated the two administrations. The Arabic version of Health Assessment Questionnaire (HAQ) was used as a comparator instrument for convergent validity.ResultsFace and content validity were satisfactory. The Arabic version of the PsAQoL was found to be relevant, understandable and easy to complete in only a few minutes. One item was excluded (item 16). It had no correlation with either the other 19 items or the total score of PsAQol. The Arabic PsAQol had excellent internal consistency (Cronbach's a = 0.926), and test‐retest reliability (r = 0.982). There was a positive correlation between the total score of the PsAQoL and the Arabic version of HAQ (Spearman's r = 0.838, p < 10−3). Exploratory factor analysis had extracted two factors explaining 55% of the total variance.ConclusionNineteen items were selected to compose the Arabic version of PsAQoL, which was found to be relevant and understandable and has excellent reliability and construct validity. The new measure will be a valuable new tool for use in routine care for patients' assessment.

show abstract

Section: Discussionsupporting

confidence: 87%

“…This model has been applied in the development of The PsAQoL scale. It has been extensively adapted into various languages (Barcelos et al., 2018; Billing et al., 2010; Gonçalves et al., 2021; Heaney et al., 2017; Kiltz et al., 2021; Leung et al., 2016; Wink et al., 2013), but there is no Arabic version.…”

Section: Introductionmentioning

confidence: 99%

Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language

Tekaya

Hajji

Rouached

et al. 2023

Musculoskeletal Care

View full text Add to dashboard Cite

show abstract

“…The PsAQoL has since been translated into other languages and validated in a range of populations including Sweden, Brazil and Holland, demonstrating its usefulness in broad populations (Billing et al., 2010 ; Gonçalves et al., 2021 ; Wink et al., 2013 ).…”

Section: Patient Reported Outcome Measurementsmentioning

confidence: 99%

Outcome measures in psoriatic arthritis: Where next?

Hackett

Coates

2022

Musculoskeletal Care

View full text Add to dashboard Cite

Objective: To provide an overview of commonly used outcome measure in psoriatic arthritis (PsA).Background: PsA is a heterogenous inflammatory arthritis, associated with psoriasis that affects between 0.1% and 2% of the population and approximately one in three patients with psoriasis. Psoriatic arthritis places a significant burden on patients' overall quality of life and is associated with a range of comorbidities. Although assessment of patients and monitoring of symptoms has greatly improved over the last 2 decades, capturing disease activity in this multisystem disease remains challenging. Previous efforts have traditionally focussed on assessment of individual disease domains, however recent evidence suggests that composite measurements, particularly those incorporating patient reported outcomes may not only help monitor disease activity more accurately, but also help in accurately validating therapy outcomes in PsA patients.Purpose: This review discusses currently used outcome measurements in PsA and also highlights the importance of emerging measurements such as biomarkers and their possible role in capturing treatment response. K E Y W O R D S outcomes measurements, PROM, psoriatic arthritis 1 | INTRODUCTION Psoriatic arthritis (PsA) is a heterogenous condition with musculoskeletal involvement, manifesting as a variety of symptoms including arthritis, dactylitis, enthesitis and axial involvement (Coates and Helliwell, 2017). In addition to musculoskeletal symptoms, patients with PsA have other symptoms such as nail disease, which affects between 63% and 83% of patients (Nieradko-Iwanicka, 2017). Along with the varied nature of symptoms, the repercussions on patients are equally as diverse. Patients with PsA have an increased risk of comorbidities such as cardiovascular disease, metabolic syndromes, depression, inflammatory bowel disease and anxiety. In order to measure the impact of PsA on patients, a range of outcomes measures have been developed to ascertain disease impact and help monitor response to treatment in both clinical trials and the realworld settings. Despite the development of a range of outcome measures for patients, agreement as to the exact measure that should be utilized remains a challenge. Recent recommendations from the TIght Control Of Psoriatic Arthritis (TICOPA) trial have highlighted the need and importance of regular assessment of disease activity by clinicians, as well as the critical role patients play in capturing their own concerns (Coates et al., 2015). To capture these outcome measurements, The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) PsA working group developed a This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…As noted, there are many examples of RMT based needs fulfillment. One further example is the 20-item Psoriatic Arthritis Quality of Life Questionnaire (PSORIQoL), first developed in 2004 with some 60+ language versions and most recently translated to Brazilian Portuguese 23 , 24 . This is a binary-response interval cored RMT application, although it has yet to be transformed to a bounded ratio scale for needs-fulfillment QoL assessment.…”

Section: Disease Specific Patient Reported Outcomes Claimsmentioning

confidence: 99%

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)

Langley

2022

Innov Pharm

View full text Add to dashboard Cite

Fundamental measurement is the basis for a rational assessment of patient reported outcome (PRO) value claims; both as response to therapy and the submission of credible and evaluable value claims to formulary committees and other health system decision makers. It is important to emphasize the importance of creating interval and ratio scales as opposed to nominal and ordinal scales to support value claims; a recognition that follows from acceptance of conjoint simultaneous measurement and the contribution of Rasch or modern measurement theory (RMT). Failure to appreciate the role of RMT has led thousands of researchers simply to apply numerals to events, inappropriately applying the techniques of classical statistical analysis, with the result that all that is produced are ordinal PRO scores. Instead, we should be aiming for interval and ratio scores based on a comprehensible latent trait and the application of the Rasch model. The purpose of this brief commentary is to review the measurement properties of PRO value claims for mavacamten (Camzyos; Bristol Myers Squibb) in symptomatic hypertrophic cardiomyopathy (SHCM) and to judge whether they have any validity when judged against the requirements of modern measurement theory. The assessment includes both the recent evidence report by the Institute for Clinical and Economic Review (ICER) for mavacamten as well as pivotal randomized trial (RCT) value claims that combine clinical endpoints with PROs that fail the standards of fundamental evidence. These include the Kansas City Cardiomyopathy Questionnaire (KCCQ), the New York Heart Association (NYHA) functional classification and the EuroQuol EQ-5D-5L multiattribute health related quality of life (HRQoL) preference instrument. The review concludes that apart from purely clinical claims based on the various pivotal trials, there are no PRO claims for mavacamten in SHCM that meet the required measurement standards.

show abstract

Psoriatic Arthritis Quality of Life Questionnaire: translation, cultural adaptation and validation into Brazilian Portuguese language

Cited by 4 publications

References 18 publications

Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language

Psoriatic Arthritis Quality of Life questionnaire: Translation, cultural adaptation and validation into Arabic language

Outcome measures in psoriatic arthritis: Where next?

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)

Contact Info

Product

Resources

About